FIELD: organic chemistry, chemical technology, medicine, pharmacy.
SUBSTANCE: invention relates to derivatives of aryl carboxylic acids and describes a compound of the formula (I):
, wherein groups R1, R2, R3, R4 and groups R5 and R6 when they are joined to carbon atom can be similar or different and mean hydrogen, halogen atom, hydroxy-group or optionally substituted group taken among alkyl, alkoxy-group, phenyl, carboxylic acid or sulfonic acid; one or both substitutes R5 and R6 can mean oxo-group also if they are joined to carbon atom; if R5 and R are joined to nitrogen atom then they mean hydrogen atom, hydroxy-group or optionally substituted alkyl or benzyl; X means heteroatom taken among oxygen and sulfur atom or NH; Ar means optionally substituted bivalent a single or condensed aromatic or heterocyclic group wherein aromatic ring represents phenyl, naphthyl and heterocyclic group represents furan; R7 means hydrogen, halogen atom, alkoxy-group, alkyl, or it forms a bond with the adjacent group R8; R8 means hydrogen atom, hydroxy-, alkoxy-group, alkyl or optionally substituted benzyl; or R8 forms a bond in common with R7; R9 means hydrogen atom or optionally substituted group taken among alkyl, phenyl or benzyl group; R10 means hydrogen atom or optionally substituted group taken among alkyl, phenyl or benzyl group; Y means oxygen atom or NR12 wherein R12 means hydrogen atom, alkyl or benzyl; R10 and R12 can form in common five- or six-membered cyclic structure comprising carbon atoms that involves optionally one or some heteroatoms taken among oxygen, sulfur or nitrogen atoms; a binding group represented by the formula: -(CH2)n-(O)m- can be joined through nitrogen atom or through carbon atom and wherein n means a whole number from 1 to 4; m means a whole number from 0 to 1 under condition that when a binding group is joined through carbon atom then R5 either R6 represents oxo-group; Y means oxygen atom; R9 doesn't mean hydrogen atom; or its derivatives, analogs, its tautomeric forms, its stereoisomers, its polymorphic forms, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates. Also, invention describes methods for preparing compounds of the general formula (I), intermediate compounds and methods for their preparing, a pharmaceutical composition eliciting activity with respect to hPPRα, hPPRγ and inhibitory activity with respect to HMG-CoA-reductase and involving compound of the formula (I). Also, invention relates to methods for prophylaxis and treatment of different diseases caused by above said activity, a method for reducing the total cholesterol level and a method for reducing the glucose level. Invention provides preparing new compounds eliciting valuable biological properties.
EFFECT: improved preparing methods, valuable medicinal properties of compounds.
27 cl, 64 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARING (VARIANTS) AND USING AS AGENTS AGAINST OBESITY AND HYPERHOLESTEROLEMIA | 2000 |
|
RU2278114C2 |
BETA-ARYL-ALPHA-HYDROXY-SUBSTITUTED ALKYLCARBOXYLIC ACIDS, METHODS FOR THEIR PREPARING, INTERMEDIATE COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OR PROPHYLAXIS OF DISEASES BASED ON NEW COMPOUNDS | 1998 |
|
RU2235094C2 |
BENZOXAZINE OR PYRIDOOXAZINE COMPOUNDS, METHODS OF THEIR SYNTHESIS, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS SHOWING ANTIBACTERIAL ACTIVITY, METHODS OF TREATMENT OF BACTERIAL INFECTIONS | 1996 |
|
RU2191179C2 |
DERIVATIVES OF INDOLE, METHOD FOR THEIR PREPARING AND THEIR APPLYING | 2001 |
|
RU2259998C2 |
METHOD FOR PREPARING CHIRAL 1,4-DISUBSTITUTED PIPERAZINES | 2003 |
|
RU2315044C2 |
DERIVATIVES OF PYRROLOPYRIMIDINE, METHOD FOR PREPARING AND THEIR USING | 2001 |
|
RU2263676C2 |
4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | 2020 |
|
RU2822388C2 |
PHARMACEUTICAL PRODUCT CONTAINING INHIBITOR OF SODIUM DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2811864C1 |
NOVEL PHOSPHATE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2617682C2 |
PPARγ RECEPTOR MODULATING NOVEL COMPOUNDS AND USE THEREOF IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | 2004 |
|
RU2401836C2 |
Authors
Dates
2005-03-10—Published
1998-10-26—Filed